Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide,
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, ...
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback